Varenicline Tablet, Film Coated
Product Images NDC 27241-173

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 27241-173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0.5mg (Varenicline 05mg)

0.5mg (Varenicline 05mg)
Each film-coated tablet contains 0.85 mg varenicline tartrate equivalent to 0.5 mg varenicline free base. The tablets are stored at a temperature range of 68°F to 77°F with excursions permitted at 59°F to 86°F. They should be dispensed in tight, child-resistant containers and kept out of reach of children. The accompanying prescribing information should be consulted before use.*
FDA Label Image

1mg (Varenicline 1mg)

FDA Label Image

1mgback (Varenicline Continuing B)

FDA Label Image

1mgfront (Varenicline Continuing F)

1mgfront (Varenicline Continuing F)
This is a medication schedule outlining the dosage and timing for taking Varenicline tablets. It specifies taking one tablet in the morning and one in the evening for specified days (Day 22-28, Day 15-21, Day 8-14, and Day 1-7) as part of a continuing week. It also mentions the tablet strength as 1mg.*
FDA Label Image

Continuing-back (Varenicline Continuing Week B)

Continuing-back (Varenicline Continuing Week B)
This text provides detailed information about Varenicline tablets in two different strengths: 0.5 mg and 1 mg. Each tablet contains varenicline tartrate equivalent to the specified free base amount. The text includes dosage instructions and advises referring to the Medication Guide for further details. The tablets should be stored within a certain temperature range. The product is marketed by Ajanta Pharma USA Inc. and manufactured in India. It also includes codes for identification purposes.*
FDA Label Image

Contnuing-front (Varenicline Continuing Week F)

Contnuing-front (Varenicline Continuing Week F)
This is a medication schedule for Varenicline tablets. The tablets are classified by their dosage strength (0.5 mg or 1 mg) and the specific days when they should be consumed. The schedule specifies taking one tablet in the morning and one in the evening on certain days. It starts with the Starting Week, then continues with three subsequent Continuing Weeks. The purpose of this schedule is likely to outline a gradual dosing regimen for the medication.*
FDA Label Image

1mg-carton (Varenicline Continuingmonthbox)

FDA Label Image

Varenicline-figure3 (Varenicline Figure3)

Varenicline-figure3 (Varenicline Figure3)
This is a chart showing the Continuous Abstinence Rate during Nontreatment Follow-Up for two groups, one taking Varenicline Tablet 10mg and the other taking Placebo. The percentage of participants who remained continuously abstinent from smoking is plotted over the course of several weeks of nontreatment follow-up. Time is measured in weeks along the X-axis and the percentage of continuous abstinent participants is shown on the Y-axis.*
FDA Label Image

Starting-month-box (Varenicline Startingmonthbox)

FDA Label Image

Varenicline-structure (Varenicline Structure)

FDA Label Image

Varenicline_figure1 (Varenicline Fig1)

FDA Label Image

Varenicline-figure2 (Varenicline Figure2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.